

# FY4/20 2Q Supplementary Materials

# AIN HOLDINGS INC.

December 3, 2019

### 1. Consolidated Results

■Year-on-Year (¥ million)

	FY4/19 2Q results	FY4/20 2Q results	YoY change	YoY change(%)
Net sales	131,781	145,851	+14,070	+10.7
Gross profit % of net sales	21,413 <b>16.2</b>	23,660 <b>16.2</b>	+2,247	+10.5
SG&A expenses % of net sales	14,681 11.1	15,305 10.5	+624	+4.3
Operating income % of net sales	6,731 <b>5.1</b>	8,354 <b>5.7</b>	+1,623	+24.1
Ordinary income % of net sales	7,018 <b>5.3</b>	8,762 <b>6.0</b>	+1,744	+24.9
Profit attributable to owners of parent % of net sales	3,639 2.8	4,622 <b>3.2</b>	+983	+27.0
Earnings per share(¥)	102.73	130.47	+27.74	+27.0

Figures in the table are rounded down

■Vs Plan (¥ million)

	FY4/20 2Q plan	FY4/20 2Q results	Vs plan change	Vs plan change(%)
Net sales	144,050	145,851	+1,801	+1.3
Gross profit % of net sales	23,890 <b>16.6</b>	23,660 <b>16.2</b>	(230)	(1.0)
SG&A expenses % of net sales	15,390 <b>10.7</b>	15,305 10.5	(85)	(0.6)
Operating income % of net sales	8,500 <b>5.9</b>	8,354 <b>5.7</b>	(146)	(1.7)
Ordinary income % of net sales	8,750 <b>6.1</b>	8,762 <b>6.0</b>	+12	+0.1
Profit attributable to owners of parent % of net sales	4,640 <b>3.2</b>	4,622 <b>3.2</b>	(18)	(0.4)
Earnings per share(¥)	130.97	130.47	(0.50)	(0.4)

### 2. Segment Information (Dispensing Pharmacy Business)

■Year-on-Year (¥ million)

	FY4/19 2Q results	FY4/20 2Q results	YoY change	YoY change(%)
Net sales	116,376	130,499	+14,123	+12.1
Gross profit % of net sales	15,036 12.9	17,390 13.3	+2,354	+15.7
SG&A expenses % of net sales	7,419 <b>6.4</b>	7,487 <b>5.7</b>	+68	+0.9
Operating income % of net sales	7,616 <b>6.5</b>	9,902 <b>7.6</b>	+2,286	+30.0
Segment income % of net sales	7,875 <b>6.8</b>	10,185 <b>7.8</b>	+2,310	+29.3

Figures in the table are rounded down

■Vs Plan (¥ million)

	FY4/20 2Q plan	FY4/20 2Q results	Vs plan change	Vs plan change(%)
Net sales	127,690	130,499	+2,809	+2.2
Gross profit % of net sales	17,330 <b>13.6</b>	17,390 <b>13.3</b>	+60	+0.3
SG&A expenses % of net sales	7,290 <b>5.7</b>	7,487 <b>5.7</b>	+197	+2.7
Operating income % of net sales	10,040 <b>7.9</b>	9,902 <b>7.6</b>	(138)	(1.4)
Segment income % of net sales	10,260 <b>8.0</b>	10,185 <b>7.8</b>	(75)	(0.7)

Figures in the table are rounded down

Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income

Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income

## 3. Segment Information (Cosmetic and Drug Store Business)

■Year-on-Year (¥ million)

	FY4/19 2Q results	FY4/20 2Q results	YoY change	YoY change(%)
Net sales	12,544	13,099	+555	+4.4
Gross profit % of net sales	4,698 <b>37.5</b>	5,073 <b>38.7</b>	+375	+8.0
SG&A expenses % of net sales	4,191 <b>33.4</b>	4,649 <b>35.5</b>	+458	+10.9
Operating income % of net sales	506 <b>4.0</b>	423 <b>3.2</b>	(83)	(16.4)
Segment income % of net sales	552 4.4	442 <b>3.4</b>	(110)	(19.9)

Figures in the table are rounded down

■Vs Plan (¥ million)

	FY4/20 2Q plan	FY4/20 2Q results	Vs plan change	Vs plan change(%)
Net sales	13,900	13,099	(801)	(5.8)
Gross profit % of net sales	5,300 <b>38.1</b>	5,073 <b>38.7</b>	(227)	(4.3)
SG&A expenses % of net sales	4,700 <b>33.8</b>	4,649 <b>35.5</b>	(51)	(1.1)
Operating income % of net sales	600 <b>4.3</b>	423 <b>3.2</b>	(177)	(29.5)
Segment income % of net sales	608 4.4	442 <b>3.4</b>	(166)	(27.3)

Figures in the table are rounded down

Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income

Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income

## 4. Sales Verification

■ Dispensing Pharmacy Business (YoY) (%	■ Dispensing Pharmacy Business (Vs Plan) (%)
---	--

	Net sales	Prescription volume	Average prescription price		Net sales	Prescription volume	Average prescription price
Same store (947)	+2.9	(0.3)	+3.3	Same store (947)	+2.5	+0.7	+1.8
Store openings in the previous year (151)	+429.7	+378.7	+12.7	Store openings in the previous year (151)	+4.1	+2.2	+1.9
Total (1,106)	+12.0	+8.0	+3.9	Total (1,106)	+2.0	+0.1	+1.9

# ■ Cosmetic and Drug Store Business (YoY) (%) ■ Cosmetic and Drug Store Business (Vs Plan) (%)

	Net sales	Number of customers	Average spending per customer		Net sales	Number of customers	Average spending per customer
Same store (43)	(1.0)	+1.3	(2.3)	Same store (43)	(5.9)	+0.8	(6.7)
Store openings in the previous year (7)	+523.8	+608.1	(11.9)	Store openings in the previous year (7)	+2.9	+9.7	(6.1)
Total (60)	+4.4	+8.6	(3.8)	Total (60)	(5.8)	+1.1	(6.8)

#### 5. Consolidated Balance Sheet

■ Assets (¥ million)

	End-FY4/19 2Q	End-FY4/19	End-FY4/20 2Q	Change
Cash on hand and in banks	57,337	48,091	44,441	(3,650)
Notes and accounts receivable	10,835	12,771	14,932	+2,161
Inventories	12,088	12,898	14,439	+1,541
Total current assets	91,323	85,446	84,230	(1,216)
Buildings and structures,net	15,732	16,352	16,558	+206
Land	10,376	10,394	10,658	+264
Lease assets	762	571	415	(156)
Total property, plant and equipment	29,339	30,186	30,901	+715
Goodwill	40,993	45,249	43,119	(2,130)
Lease assets	11	7	6	(1)
Total intangible fixed assets	43,064	47,577	45,761	(1,816)
Investments in securities	2,254	1,795	2,096	+301
Deferred tax assets	3,915	4,284	4,260	(24)
Deposits and guarantees	11,540	15,133	15,401	+268
Total investments and other assets	20,755	25,751	26,836	+1,085
Total fixed assets	93,159	103,515	103,499	(16)
Total deferred assets	81	59	37	(22)
Total assets	184,564	189,021	187,767	(1,254)

Figures in the table are rounded down

Change:End-FY4/20 2Q compared with end-FY4/19

#### ■ Liabilities and Net Assets

(¥ million)

	End-FY4/19 2Q	End-FY4/19	End-FY4/20 2Q	Change			
Accounts payable	42,131	44,794	45,639	+845			
Short-term debt	8,143	5,571	4,555	(1,016)			
Lease obligations	367	318	254	(64)			
Total current liabilities	72,397	73,744	71,885	(1,859)			
Long-term debt	8,660	5,985	4,079	(1,906)			
Lease obligations	541	401	269	(132)			
Total long-term liabilities	13,631	11,355	9,301	(2,054)			
Total liabilities	86,028	85,099	81,186	(3,913)			
Common stock	21,894	21,894	21,894	-			
Capital surplus	20,500	20,500	20,500	-			
Retained earnings	56,137	61,526	64,200	+2,674			
Total shareholders' equity	98,530	103,920	106,594	+2,674			
Total net assets	98,535	103,922	106,580	+2,658			
Total liabilities and net assets	184,564	189,021	187,767	(1,254)			
Figures in the table are rounded down	s in the table are rounded down Change:End-FY4/20 2Q compared with end-FY4/19						

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled ¥3,857million

# 6. FY4/20 Plan (Consolidated)

(¥ million)

	FY4/18 results	FY4/19 results	FY4/20 plan	YoY change	YoY change (%)
Net sales	268,385	275,596	300,330	+24,734	+9.0
Gross profit % of net sales	47,993 <b>17.9</b>	45,363 <b>16.5</b>	<b>50,540</b> 16.8	+5,177	+11.4
SG&A expenses % of net sales	28,370 <b>10.6</b>	29,295 <b>10.6</b>	31,840 10.6	+2,545	+8.7
Operating income % of net sales	19,622 <b>7.3</b>	16,067 <b>5.8</b>	18,700 6.2	+2,633	+16.4
Ordinary income % of net sales	20,129 <b>7.5</b>	16,637 <b>6.0</b>	19,200 6.4	+2,563	+15.4
Profit attributable to owners of parent <b>% of net sales</b>	10,567 3.9	9,029 <b>3.3</b>	10,130 3.4	+1,101	+12.2
Earnings per share(¥)	310.08	254.87	285.94	+31.07	+12.2
Annual dividend (¥)	50.00	55.00	55.00	-	0.0

Figures in the table are rounded down

Change:FY4/20 plan compared with FY4/19 results

#### 7. Transition of Store Openings

#### ■ Number of Store Openings in Dispensing Pharmacy Business

	FY4/12	FY4/13	FY4/14	FY4/15	FY4/16	FY4/17	FY4/18	FY4/19	FY4/20 2Q
Organic	27	38	36	40	32	27	25	23	5
M&A	28	38	26	119	110	182	11	134	5
Total	494	560	616	754	881	1,066	1,029	1,132	1,106

#### ■ Number of Store Openings in Cosmetic and Drug Store Business

	FY4/12	FY4/13	FY4/14	FY4/15	FY4/16	FY4/17	FY4/18	FY4/19	FY4/20 2Q
Organic	7	7	3	3	5	9	4	7	10
Total	56	61	59	56	52	52	48	54	60

#### Inquiries related to this presentation should be addressed to

AIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.

